Why supplements need no approval to be sold

A person reading about a longevity compound generally assumes that somebody checked. The compound is on sale, the label describes what it does, and the site selling it cites research. In the United States, none of that requires anyone outside the company to have verified anything.

This is not a loophole. It is the design of the law, and understanding it explains more about the longevity supplement market than any individual product page.

Nobody approves it first

The Food and Drug Administration states its position plainly: manufacturers and distributors of dietary supplements and dietary ingredients are prohibited from marketing products that are adulterated or misbranded, and are themselves responsible for evaluating the safety and labeling of their products before marketing.

The agency’s own role is described as subsequent. It has the authority to take action against an adulterated or misbranded dietary supplement product after it reaches the market.

So the sequence is: the company decides the product is safe and correctly labelled, the product goes on sale, and the regulator may act afterwards if something is wrong. For a drug the sequence runs the other way, and that difference is the whole of it.

What a product may claim, and on what terms

The permitted category is the structure/function claim: a statement that a product supports some structure or function of the body. Supports healthy aging. Supports cellular energy. Supports cognitive function.

Such a claim may be made without demonstrating it, on one condition — the label must carry the disclaimer in the exact wording the FDA specifies: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

That sentence is printed in small type on the back of almost every supplement sold, and most buyers read it as legal boilerplate. It is not boilerplate. It is the disclosure that the claim on the front has not been evaluated by anyone but the seller.

The company then notifies the agency of the claim — no later than 30 days after first marketing the supplement with it. The notification follows the sale rather than preceding it.

Silence is not agreement

The final piece is the one most easily misread, and the FDA addresses it directly.

The agency reviews these notifications and typically writes to a firm only if it objects to the statements. If it does not object, it generally does not respond or otherwise inform the notifier that its review is complete. And a response, or the absence of one, should not be read as a statement about the product’s compliance with other legal requirements.

So a company can truthfully say it notified the FDA and received no objection. That sentence, on a product page, sounds like clearance. It describes the normal case in which nothing happened.

What this looks like in practice

Take a compound where the trials do exist. A 2026 meta-analysis pooled 15 randomised trials of oral NMN and found no significant effect on body weight, BMI, fasting glucose, HbA1c, lipid profiles or systolic blood pressure, alongside good short-term tolerability.

Nothing in that result affects the compound’s right to be sold, or the wording on its label. A product may continue to state that it supports cellular energy and healthy aging, because a structure/function claim was never a claim about clinical outcomes in the first place. The sentence and the evidence are not measured against each other, because the law does not require them to be.

The gap grows wider where the evidence is thinner. Almost every measurement in this field is a surrogate endpoint — a stand-in for the outcome the buyer cares about — and the FDA reserves the language of validation for surrogates supported by clinical data. No such standard applies to what appears on a supplement bottle.

The useful conclusion

None of this makes supplements fraudulent or unsafe as a class. It makes a specific inference unavailable: that a product being sold, labelled and marketed implies that its claims were checked.

The questions that remain available are the ordinary ones. Has this compound been tested in a randomized controlled trial? What did the trial measure, and what did it find? Is the claim on the label the same claim the trial tested?

For most of the longevity shelf, the answer to the first question is no. For the compounds where it is yes, the answer to the third is usually no as well.